Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01588509 · ClinicalTrials.gov registry record · Phase 1
Transition From Alendronate to Romosozumab (AMG 785)
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01588509 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 60 participants.
The verdict
NCT01588509, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.
Interventions
- DRUG Romosozumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-03-30 |
| Est. Completion | 2012-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01588509
The ClinicalTrials.gov registry entry for NCT01588509 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Romosozumab is the first listed.
NCT01588509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01588509 about?
NCT01588509 is a clinical study titled "Transition From Alendronate to Romosozumab (AMG 785)". The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.
What is the current status of trial NCT01588509?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2012-03-30. Estimated completion is 2012-11-21.
What interventions are being tested in trial NCT01588509?
The interventions under investigation include: Romosozumab (DRUG).
Who is sponsoring clinical trial NCT01588509?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.